Advances toward LSD1 inhibitors for cancer therapy | Future Medicinal Chemistry
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine
Divalent tranylcypromine derivative as lysine-specific demethylase 1 inhibitor | SpringerLink
Frontiers | LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells | Oncology
Histone lysine specific demethylase 1 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00141D
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia | Leukemia
Table 1 from Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar
Irreversible TCP-based LSD1 inhibitors 19-24. | Download Scientific Diagram
LSD1 inhibitors in clinical trials | Download Scientific Diagram
Summary of LSD1/KDM1A inhibitors in clinical trials and clinical use. a | Download Table
Frontiers | Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia | Oncology
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Semantic Scholar
LSD1 inhibitors in clinical trials. (A) Structure of TCP-based... | Download Scientific Diagram
Molecules | Free Full-Text | Pharmacological Inhibition of LSD1 for Cancer Treatment | HTML
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine
Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021 - ScienceDirect
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy | Leukemia
Natural products as LSD1 inhibitors for cancer therapy - ScienceDirect
Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition | Haematologica
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy | Clinical Epigenetics | Full Text
GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro | Signal Transduction and Targeted Therapy
